据老夫了解， $沛嘉_老虎社区_美港股上老虎

明大教主
04-10

据老夫了解， $沛嘉医疗-B(09996)$ 神经介入原材料此前就采取国产替代、欧盟替代等措施，神介业务自美国进口的原材料在1%上下。
而瓣膜业务中原材料自美国进口的比重还不足1%。整体应该是相当有限。
且YonFlow刚刚宣布上市，不但是补齐了沛嘉医疗神介的一个弱环，今年组套销售对神介业务的助力也非常值得期待！

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":422735901643288,"tweetId":"422735901643288","gmtCreate":1744247451009,"gmtModify":1744247453695,"author":{"id":4120462527107840,"idStr":"4120462527107840","authorId":4120462527107840,"authorIdStr":"4120462527107840","name":"明大教主","avatar":"https://static.tigerbbs.com/7923b570045ef396e894082089df0a6c","vip":2,"userType":2,"introduction":"长期跟踪A、港美股，擅长结合基本面、技术面深度分析","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.30","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":12805,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>据老夫了解， <a href=\"https://laohu8.com/S/09996\">$沛嘉医疗-B(09996)$</a> 神经介入原材料此前就采取国产替代、欧盟替代等措施，神介业务自美国进口的原材料在1%上下。\n<br>\n而瓣膜业务中原材料自美国进口的比重还不足1%。整体应该是相当有限。\n<br>\n且YonFlow刚刚宣布上市，不但是补齐了沛嘉医疗神介的一个弱环，今年组套销售对神介业务的助力也非常值得期待！</body></html>","htmlText":"<html><head></head><body>据老夫了解， <a href=\"https://laohu8.com/S/09996\">$沛嘉医疗-B(09996)$</a> 神经介入原材料此前就采取国产替代、欧盟替代等措施，神介业务自美国进口的原材料在1%上下。\n<br>\n而瓣膜业务中原材料自美国进口的比重还不足1%。整体应该是相当有限。\n<br>\n且YonFlow刚刚宣布上市，不但是补齐了沛嘉医疗神介的一个弱环，今年组套销售对神介业务的助力也非常值得期待！</body></html>","text":"据老夫了解， $沛嘉医疗-B(09996)$ 神经介入原材料此前就采取国产替代、欧盟替代等措施，神介业务自美国进口的原材料在1%上下。 而瓣膜业务中原材料自美国进口的比重还不足1%。整体应该是相当有限。 且YonFlow刚刚宣布上市，不但是补齐了沛嘉医疗神介的一个弱环，今年组套销售对神介业务的助力也非常值得期待！","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/422735901643288","repostId":0,"isVote":1,"tweetType":1,"viewCount":898,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["09996"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":275,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}